Offer Durable Strength With the NINLARO® (ixazomib) Regimen for Multiple Myeloma Patients at First Relapse*1,2

*The NINLARO regimen included NINLARO + lenalidomide + dexamethasone.1

Lighthouse with waves crashing.


TOURMALINE-MM1 was a global, phase 3, randomized, double-blind, placebo-controlled clinical trial that evaluated the all-oral NINLARO regimen* vs Rd regimen* in 722 patients with relapsed and/or refractory multiple myeloma who had received at least one prior line of therapy.1,2

*The NINLARO regimen included NINLARO + lenalidomide + dexamethasone. The Rd regimen included placebo + lenalidomide + dexamethasone.1

The NINLARO regimen* was shown to significantly extend PFS compared to the Rd regimen (primary analysis)*1,2

Median PFS of 20.6 months achieved with NINLARO® (ixazomib) regimen vs 14.7 months with Rd regimen.

CI=confidence interval; HR=hazard ratio; mPFS=median progression-free survival; NE=not evaluable; PFS=progression-free survival.

Final OS Analysis
With a median follow-up of ~85 months, median OS in the ITT population was 53.6 months for patients receiving the NINLARO regimen* and 51.6 months for patients receiving the Rd regimen* (HR=0.94 [95% CI, 0.78-1.13]).1


The NINLARO triplet regimen* demonstrated a safety profile comparable to the Rd regimen*1  

Most common adverse reactions
The most common adverse reactions (≥20%) are thrombocytopenia, neutropenia, diarrhea, constipation, peripheral neuropathy, nausea, peripheral edema, rash, vomiting, and bronchitis.1

Serious adverse reactions
Serious ARs reported in ≥2% of patients in the NINLARO regimen* included diarrhea (3%), thrombocytopenia (2%), and bronchitis (2%).1

Learn more about different patient profiles, like those in your practice, who may benefit from NINLARO

Black man looking off camera and smiling.